FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022346239> ?p ?o ?g. }

• W2022346239 endingPage "750" @default.
• W2022346239 startingPage "745" @default.
• W2022346239 abstract "Infliximab, a monoclonal antibody against tumor necrosis factor-alpha, has been shown to be effective for the treatment of refractory Crohn’s disease in adult patients, but experience in pediatrics is limited. This retrospective study included 88 children and adolescents, 39 girls and 49 boys, with a median age of 14 years (range 3.3–17.9). Infliximab was indicated for active disease (66%) and/or fistulas (42%) that were refractory to corticosteroids (70%), and/or other immunosuppressive (82%) agents, and/or parenteral nutrition (20%). Patients received 1 to 17 infusions (median 4) of 5 mg/kg (range 3.8–7.3) of infliximab during a median time period of 4 months (1–17 months). Infusion reaction was noted in 13 patients (15%), with a total of 16 reactions in 450 infusions (4%). At Day 90 after the first infusion of infliximab, symptoms improved in 49% of patients, whereas 29% of patients were in remission and 13% of patients relapsed. From Day 0 to Day 90, Harvey–Bradshaw score decreased from 7.5 to 2.8 (P < 0.001), C-reactive protein from 36 to 16 mg/L (P < 0.01), and 1-hour erythrocyte sedimentation rate from 35 to 17 mm (P < 0.01). Dosage of corticosteroids decreased from to 0.59 to 0.17 mg/kg/d (P < 0.001); 53% of patients could be weaned of corticosteroids and 92% of parenteral nutrition. Treatment with infliximab is well tolerated and effective in most children and adolescents with Crohn’s disease that is refractory to conventional immunosuppressive therapy. Nevertheless, long-term efficacy remains to be shown, and further studies are urgently needed to precisely determine the best modality of continuing treatment." @default.
• W2022346239 created "2016-06-24" @default.
• W2022346239 creator A5009106515 @default.
• W2022346239 creator A5024135629 @default.
• W2022346239 creator A5025140037 @default.
• W2022346239 creator A5028681772 @default.
• W2022346239 creator A5038401549 @default.
• W2022346239 creator A5041736647 @default.
• W2022346239 creator A5047538755 @default.
• W2022346239 creator A5052113800 @default.
• W2022346239 creator A5053214578 @default.
• W2022346239 creator A5055163685 @default.
• W2022346239 creator A5065799737 @default.
• W2022346239 creator A5072622375 @default.
• W2022346239 creator A5075041815 @default.
• W2022346239 creator A5075727221 @default.
• W2022346239 creator A5075759858 @default.
• W2022346239 creator A5079333159 @default.
• W2022346239 creator A5081268394 @default.
• W2022346239 creator A5087047716 @default.
• W2022346239 creator A5091614360 @default.
• W2022346239 date "2004-11-01" @default.
• W2022346239 modified "2023-10-16" @default.
• W2022346239 title "Efficacy and Tolerance of Infliximab in Children and Adolescents with Crohn’s Disease" @default.
• W2022346239 cites W1658971169 @default.
• W2022346239 cites W1964958755 @default.
• W2022346239 cites W1971331540 @default.
• W2022346239 cites W1973123086 @default.
• W2022346239 cites W1978908714 @default.
• W2022346239 cites W1982879448 @default.
• W2022346239 cites W1997999969 @default.
• W2022346239 cites W2000518155 @default.
• W2022346239 cites W2008629972 @default.
• W2022346239 cites W2011111248 @default.
• W2022346239 cites W2014257728 @default.
• W2022346239 cites W2024162533 @default.
• W2022346239 cites W2027334329 @default.
• W2022346239 cites W2027887689 @default.
• W2022346239 cites W2028547258 @default.
• W2022346239 cites W2035092856 @default.
• W2022346239 cites W2038535814 @default.
• W2022346239 cites W2042353449 @default.
• W2022346239 cites W2049575817 @default.
• W2022346239 cites W2051096775 @default.
• W2022346239 cites W2064661856 @default.
• W2022346239 cites W2072738451 @default.
• W2022346239 cites W2077833843 @default.
• W2022346239 cites W2078367805 @default.
• W2022346239 cites W2078824920 @default.
• W2022346239 cites W2082741414 @default.
• W2022346239 cites W2094230091 @default.
• W2022346239 cites W2098638622 @default.
• W2022346239 cites W2131652664 @default.
• W2022346239 cites W2154117979 @default.
• W2022346239 cites W2321453230 @default.
• W2022346239 cites W2326330820 @default.
• W2022346239 cites W2327550736 @default.
• W2022346239 cites W4249216772 @default.
• W2022346239 doi "https://doi.org/10.1097/00054725-200411000-00008" @default.
• W2022346239 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15626892" @default.
• W2022346239 hasPublicationYear "2004" @default.
• W2022346239 type Work @default.
• W2022346239 sameAs 2022346239 @default.
• W2022346239 citedByCount "70" @default.
• W2022346239 countsByYear W20223462392012 @default.
• W2022346239 countsByYear W20223462392013 @default.
• W2022346239 countsByYear W20223462392014 @default.
• W2022346239 countsByYear W20223462392015 @default.
• W2022346239 countsByYear W20223462392016 @default.
• W2022346239 countsByYear W20223462392017 @default.
• W2022346239 countsByYear W20223462392019 @default.
• W2022346239 countsByYear W20223462392020 @default.
• W2022346239 countsByYear W20223462392021 @default.
• W2022346239 countsByYear W20223462392022 @default.
• W2022346239 crossrefType "journal-article" @default.
• W2022346239 hasAuthorship W2022346239A5009106515 @default.
• W2022346239 hasAuthorship W2022346239A5024135629 @default.
• W2022346239 hasAuthorship W2022346239A5025140037 @default.
• W2022346239 hasAuthorship W2022346239A5028681772 @default.
• W2022346239 hasAuthorship W2022346239A5038401549 @default.
• W2022346239 hasAuthorship W2022346239A5041736647 @default.
• W2022346239 hasAuthorship W2022346239A5047538755 @default.
• W2022346239 hasAuthorship W2022346239A5052113800 @default.
• W2022346239 hasAuthorship W2022346239A5053214578 @default.
• W2022346239 hasAuthorship W2022346239A5055163685 @default.
• W2022346239 hasAuthorship W2022346239A5065799737 @default.
• W2022346239 hasAuthorship W2022346239A5072622375 @default.
• W2022346239 hasAuthorship W2022346239A5075041815 @default.
• W2022346239 hasAuthorship W2022346239A5075727221 @default.
• W2022346239 hasAuthorship W2022346239A5075759858 @default.
• W2022346239 hasAuthorship W2022346239A5079333159 @default.
• W2022346239 hasAuthorship W2022346239A5081268394 @default.
• W2022346239 hasAuthorship W2022346239A5087047716 @default.
• W2022346239 hasAuthorship W2022346239A5091614360 @default.
• W2022346239 hasBestOaLocation W20223462391 @default.
• W2022346239 hasConcept C121332964 @default.
• W2022346239 hasConcept C126322002 @default.
• W2022346239 hasConcept C141071460 @default.

• next